Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rapport Therapeutics, Inc. (RAPP) since 2024 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Rapport Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 2012593.
Total stock buying since 2024: $12,354,069.
Total stock sales since 2024: $2,949,782.
Total stock option exercises since 2024: $9,000.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 81,566 | $1,771,315 | 132,420 | $2,949,782 | 5,000 | $9,000 |
| 2024 | 602,856 | $10,582,754 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-09 | 65,566 | $1,609,079 | 89,920 | $2,433,017 | 5,000 | $9,000 |
| 2025-08 | 0 | $0 | 8,500 | $130,755 | 0 | $0 |
| 2025-07 | 0 | $0 | 8,500 | $118,966 | 0 | $0 |
| 2025-06 | 0 | $0 | 8,500 | $93,525 | 0 | $0 |
| 2025-04 | 0 | $0 | 8,500 | $81,311 | 0 | $0 |
| 2025-03 | 16,000 | $162,236 | 8,500 | $92,208 | 0 | $0 |
| 2024-07 | 44,032 | $1,082,746 | 0 | $0 | 0 | $0 |
| 2024-06 | 558,824 | $9,500,008 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-17 | Ceesay Abraham (Chief Executive Officer) | Sale | 76,420 | 26.63 | 2,035,064 |
| 2025-09-15 | Bredt David (Chief Scientific Officer) | Sale | 8,500 | 24.27 | 206,303 |
| 2025-09-12 | Huber Reid M | Buy | 20,400 | 24.48 | 499,371 |
| 2025-09-12 | Paul Steven M | Buy | 41,666 | 24.73 | 1,030,608 |
| 2025-09-11 | Young Wendy B. | Buy | 3,500 | 22.60 | 79,100 |
| 2025-09-08 | Gault Cheryl (Chief Operating Officer) | Sale | 5,000 | 38.33 | 191,650 |
| 2025-09-08 | Gault Cheryl (Chief Operating Officer) | Option Ex | 5,000 | 1.80 | 9,000 |
| 2025-08-15 | Bredt David (Chief Scientific Officer) | Sale | 8,500 | 15.38 | 130,755 |
| 2025-07-15 | Bredt David (Chief Scientific Officer) | Sale | 8,500 | 14.00 | 118,966 |
| 2025-06-16 | Bredt David (Chief Scientific Officer) | Sale | 8,500 | 11.00 | 93,525 |
| 2025-04-15 | Bredt David (Chief Scientific Officer) | Sale | 8,500 | 9.57 | 81,311 |
| 2025-03-14 | Bredt David (Chief Scientific Officer) | Sale | 8,500 | 10.85 | 92,208 |
| 2025-03-13 | Ignelzi Troy A. (Chief Financial Officer) | Buy | 100 | 9.98 | 998 |
| 2025-03-12 | Young Wendy B. | Buy | 6,000 | 10.21 | 61,248 |
| 2025-03-12 | Ignelzi Troy A. (Chief Financial Officer) | Buy | 9,900 | 10.10 | 99,990 |
| 2024-07-01 | Healy James | Buy | 44,032 | 24.59 | 1,082,746 |
| 2024-06-10 | Healy James | Buy | 558,824 | 17.00 | 9,500,008 |
Insider trading activities including stock purchases, stock sales, and option exercises of RAPP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Rapport Therapeutics, Inc. (symbol RAPP, CIK number 2012593) see the Securities and Exchange Commission (SEC) website.